COMMUNIQUÉS West-GlobeNewswire

NANOBIOTIX lance une augmentation de capital par construction accelerée d'un livre d'ordre
30/10/2017
NANOBIOTIX LANCE UNE AUGMENTATION DE CAPITAL PAR CONSTRUCTION ACCELEREE D'UN LIVRE D'ORDRE Paris, France, et Cambridge, Massachusetts, USA, 30 octobre 2017 - NANOBIOTIX (la « Société ») (Euronext: NANO - ISIN: [...]
NANOBIOTIX launches capital increase by means of an accelerated bookbuild offering
30/10/2017
NANOBIOTIX LAUNCHES CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOKBUILD OFFERING Paris, France and Cambridge, Massachusetts, October 30, 2017 - NANOBIOTIX (the " Company ") (Euronext: NANO - ISIN: FR0011341205), a [...]
Ascom wins order to supply advanced nurse call solution for elderly care facilities in Norway
30/10/2017
BAAR, Switzerland, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Ascom (SWX:ASCN.SW) secures a long term contract with the Drammen municipality in Norway to modernize and improve the communication infrastructure of its elderly care [...]
Ossur Hf : Transactions in relation to share buyback program
30/10/2017
Announcement from Össur hf. No. 79/2017 Reykjavík, 30 October 2017 On 15 August 2017, Össur hf. initiated a share buy-back program, see Company announcement no. 59/2017. The purpose of the share buyback program is to [...]
Ossur Hf: Insider trading
30/10/2017
Announcement Össur hf. N o. 78/2017 Viðskipti með eigin bréf/ transaction in own financial instruments Nafn/Name: Össur hf. Dagsetning viðskipta/Date of transaction: 30 October 2017 Kaup eða sala/Buy or Sell: Sell [...]
FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants
30/10/2017
FIT Biotech Oy Company release October 30, 2017 at 4:00 pm FIT Biotech Oy's Board of Directors has decided on the issue of Convertible Notes and Warrants On September 26, 2016, the Board of Directors of FIT Biotech Oy ( [...]
Vascular Dynamics Interim Data on MobiusHD Presented at TCT Conference Shows Significant Reductions in Ambulatory Systolic Blood Pressure At Six Months
30/10/2017
Company Has Initiated Pivotal Trial for the MobiusHD in the US and EU MOUNTAIN VIEW, Calif., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Vascular Dynamics, Inc., a privately held medical device company developing novel solutions [...]
RAMSAY GENERALE DE SANTE : Mise à disposition du Document de référence 2017
30/10/2017
Mise à disposition du document de référence au 30 juin 2017 Ramsay Générale de Santé annonce le dépôt de son document de référence au 30 juin 2017 auprès de l'Autorité des Marchés Financiers (AMF) le 27 octobre 2017 [...]
Minerva Neurosciences to Report Third Quarter 2017 Financial Results and Business Updates on November 6, 2017
30/10/2017
Management to host conference call WALTHAM, Mass., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat [...]
Advanced Bifurcation Systems Announces Appointment of Chief Financial Officer
30/10/2017
LOS ANGELES, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Advanced Bifurcation Systems ("ABS" or the "Company"), a clinical stage medical device company developing an innovative stenting platform which overcomes the limitations of [...]
Alpha Tau Medical Initiates First Clinical Trial in Italy to Treat Cancer with Alpha Radiation
30/10/2017
TEL AVIV, Israel, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Alpha Tau Medical is happy to announce its first clinical trial in Italy. The study at IRST , Meldola, will evaluate the feasibility, safety and efficacy of Alpha DaRT [...]
ERRATUM: NEOVACS : RÉSULTATS SEMESTRIELS 2017 ET POINT SUR LES AVANCÉES OPÉRATIONNELLES
30/10/2017
Correction du communiqué 17:45 27.10.2017 CEST. Explication de la modification: La date de diffusion des données de preuve de concept préclinique dans le diabète de type 1 reste inchangée par rapport aux annonces [...]
ERRATUM: NEOVACS PROVIDES BUSINESS UPDATE AND ANNOUNCES HALF-YEAR 2017 FINANCIAL RESULTS
30/10/2017
This is a correction of the announcement from 17:45 27.10.2017 CEST. Reason for the correction:the release date of the data for Type 1 Diabete preclicical proof of concept remains unchanged compared to previous [...]
Affimed Announces Third Quarter 2017 Financial Results and Corporate Update Conference Call
30/10/2017
Heidelberg, Germany, October 30, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today announced that on [...]
FIT Biotech Oy: Conversion of FIT Biotech Oy's Convertible Capital Notes into shares
30/10/2017
FIT Biotech Oy Company release October 30, 2017 at 10:00 AM EET Conversion of FIT Biotech Oy's Convertible Capital Notes into shares Related to Convertible Note and Warrant Programmes established on September 26, 2016 [...]
Ossur Hf : Trading of Össur shares to be concentrated on Nasdaq Copenhagen from 6 December 2017
30/10/2017
Announcement no. 77/2017 30 October 2017 Trading of Össu r shares to be concentrated on Nasdaq Copenhagen from 6 December 2017 Trading of Össur shares will soon be concentrated on Nasdaq Copenhagen following Nasdaq [...]
MITHRA COMPLETES RECRUITMENT FOR ESTELLE® PHASE III STUDY IN US & CANADA
30/10/2017
PRESS RELEASE MITHRA COMPLETES RECRUITMENT FOR estelle® phase iii study in US & Canada Estelle ® Phase III study in US/Canada remains on track to report top line data in Q1 2019 Study recruited 2148 women in total; [...]
ESPERITE (ESP) : L1 Capital subscribes to the Ninth tranche of investment today
30/10/2017
Amsterdam, The Netherlands - 30 October 2017 Esperite N.V. (Euronext: ESP, "Esperite" or "the Group") announces that today the Ninth Tranche of EUR 250,000 is issued as a private placement of 25 convertible notes (the " [...]
Novartis to present first of its kind evidence for Cosentyx® on potential to maintain mobility in patients with AS and PsA
30/10/2017
Long-term 4-year data in ankylosing spondylitis (AS) and 24-weeks data in psoriatic arthritis (PsA) to be presented at the 2017 ACR/ARHP Annual Meeting[1],[2] Structural disease progression is a major concern for AS and [...]

Pages